** Elanco Animal Health's ELAN.N shares rise 8.83% to $10.35 premarket
** Company, which makes drugs for animals, reports Q1 revenue of $1.19 billion vs est $1.17 billion - LSEG
** Raises annual forecast to be between $4.51 billion and$4.58 billion vs prior expectation of $4.45 billion to $4.51 billion
** Elanco says its outlook incorporates current estimate for tariff net impact between $16 million and $20 million to adjusted core profit
** Company's updated tariff exposure appears manageable, which was a concern heading into the print, says brokerage Leerink
** Elanco posts Q1 adjusted profit of 37 cents/shr vs est 31 cents/shr
** As of last close, stock down 22%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。